drugset / Trial / NCT04149171
Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Study Design: Single-center, not-randomized, open-label, two-arms controlled pilot clinical trial. Health Condition: Patients with severe trauma with a need for transfusion and categorized as priority 0 or 1 according to the Catalan Health Service (CatSalut) Polytrauma Code (PPT)
Timeline
- Start
- 2018-09-26
- Primary completion
- 2020-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BLOOD CELLS, RED | Unknown | — | — |
| Comparator | Fibrinogen Concentrate | Protein / enzyme biologic | — | — |
| Comparator | Tranexamic Acid | Small molecule | — | — |
Indications
No indication recorded.